Tower House Partners’s Charles River Laboratories CRL Stock Holding History

Tower House Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$7.77M	Buy	35,678 +1,219	+4%	+$266K	46.23%	1
2022 Q3	$6.78M	Sell	34,459 -15,011	-30%	-$3.24M	27.97%	3
2022 Q2	$10.6M	Sell	49,470 -5,530	-10%	-$1.35M	31.02%	3
2022 Q1	$15.6M	Sell	55,000 -33,925	-38%	-$10.5M	27.22%	3
2021 Q4	$33.5M	Buy	88,925 +686	+0.8%	+$267K	28.7%	3
2021 Q3	$36.4M	Sell	88,239 -34,974	-28%	-$14.5M	20.66%	3
2021 Q2	$45.6M	Sell	123,213 -34,028	-22%	-$11.4M	23.73%	2
2021 Q1	$45.6M	Sell	157,241 -29,897	-16%	-$8.31M	22.18%	2
2020 Q4	$46.8M	Sell	187,138 -22,862	-11%	-$5.44M	22.81%	2
2020 Q3	$47.6M	Sell	210,000 -20,000	-9%	-$4.15M	25.47%	2
2020 Q2	$40.1M	Buy	+230,000	New	+$36.7M	19.4%	2

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Tower House Partners's CRL Position: Q4 2022 in Review

Tower House Partners increased its Charles River Laboratories (CRL) stake by 3.5% in Q4 2022, buying an estimated $266K and bringing the position to 35,678 shares worth $7.77M. The position accounts for 46.23% of the portfolio, ranked #1.

Tower House Partners first reported a position in CRL in Q2 2020 and has held it in 11 quarters since. The position peaked at $47.6M in Q3 2020. 627 funds tracked by Wall St. Rank hold CRL as of Q4 2022.

Tower House Partners held 35,678 shares of Charles River Laboratories worth $7.77M as of Q4 2022.
Tower House Partners bought 1,219 Charles River Laboratories shares in Q4 2022, an estimated $266K.
Charles River Laboratories made up 46.23% of Tower House Partners's portfolio in Q4 2022, its #1 holding.
Tower House Partners first reported a position in Charles River Laboratories in Q2 2020 and has held it in 11 quarters since.
Tower House Partners's Charles River Laboratories position peaked at $47.6M in Q3 2020.
627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2022.

Based on Tower House Partners's 13F filing for Q4 2022, filed 14 Feb 2023.